Highly active antiretroviral therapy

British Medical Journal

Volumn 330, Issue 7493, 2005, Pages 681-682

  Murri, Rita ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

CLINICAL PROTOCOL; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MONITORING; DRUG TOLERABILITY; EDITORIAL; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION RISK; LYMPHOCYTE COUNT; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; SYMPTOM; TREATMENT FAILURE; VIREMIA; VIRUS MUTATION; VIRUS REPLICATION; NOTE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; TREATMENT FAILURE;

EID: 16244419781     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.330.7493.681     Document Type: Editorial

References (12)

1. Sabin CA, Hill T, Lampe F, Matthias R, Baghani S, Gilson R, et al. Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. BMJ 2005;330:695-8.
2. Bangsberg DR, Porco TC, Kagay C, Charlebois ED, Deeks SG, Guzman D, et al. Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimatese. J Infect Dis 2004;190:162-5.
3. D'Arminio Monforte A, Cozzi Lepri A, Rezza G, Pezzotti P, Antinori A, Phillips AN et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. AIDS 2000;14:499-507.
4. Ammassari A, Murri R, Pezzotti P, Trotta MP, Ravasio L, De Longis P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001;28:445-9.
5. Justice AC, Rabeneck L, Hays RD, Wu AW, Bozzette SA. Sensitivity, specificity, reliability, and clinical validity of provider-reported symptoms: a comparison with self-reported symptoms. J Acquir Immune Defic Syndr 1999;21:126-33.
6. Guidelines for the use of antiretroviral agents in HTV-1 infected adults and adolescents. 29 October 2004. http://aidsinfo.nih.gov/guidelines/adult/ AH_102904.pdf (accessed 10 March 2005).
7. Garcia F, De Lazzari E, Plana M, Castro P, Mestre G, Norndedu M, et al. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count J Acquir Immune Defic Syndr 2004;36:702-13.
8. Hunt PW, Deeks SG, Rodriguez B, Valdez H, Shade SB, Abrams DI, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 2003;17:1907-15.
9. Centers for Diseases Control. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Morb Mortal Wkly Rep MMWR 1998;47(RR-5):1-41.
10. Badri SM, Adeyemi OM, Max BE, Zagorski BM, Barker DE. How does expert advice impact genotypic resistance testing in clinical practice? Clin Infect Dis 2003;37:708-13.
11. Raffanti SP, Fusco JS, Sherrill BH, Hansen NI, Justice AC, D'Aquila R, et al. Effect of persistent moderate virernia on disease progression during HIV therapy. J Acquir Immune Defic Syndr 2004;37:1147-54.
12. The PLATO Collaboration. Predictors of trend in CD4-positive T-cell count and mortality among HTV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004;364:51-62.